Oncology Practice Management - December 2014, Vol 4, No 8

View Digital Edition
In an ideal practice management world, every unique coding situation would be carefully explained within the Amer­ican Medical Association (AMA) Curent Procedural Terminology (CPT) codebook or within the CPT Changes: An Insider’s View manual. The rules for coding and compliance would be black and white, and they would be applied consistently from insurance payer to insurance payer. Read More ›

Those who care for patients with cancer are special. Clinical team and staff members come to work daily not just for a job, but because they care and want to be a part of helping their friends, neighbors, and community battle an insidious disease. Most of us have loved ones who were touched by cancer, and we bring unique, appreciated, and caring attention to those who we serve. Read More ›

The 2014 elections are complete, and we now know the makeup of the next US Congress. Even though Republicans picked up more than the 6 seats needed to take control of the Senate, it may not mean that significant healthcare changes are imminent. As the congressional landscape transforms, legislators will have to address the following issues. Read More ›

Gilead offers eligible patients receiving treatment with Zydelig (idelalisib) ease of access, affordability, and adherence support through its patient assistance program, Zydelig AccessConnect. Zydelig is a kinase inhibitor approved for the treatment of relapsed follicular B-cell non-Hodgkin lymphoma, relapsed small lymphocytic lymphoma, and in combination with rituximab in the treatment of relapsed chronic lymphocytic leukemia. Read More ›

Chronic lymphocytic leukemia (CLL), a cancer of B-cell lymphocytes, is the most common type of leukemia in Western adult patients. According to the Leukemia & Lymphoma Society, more than 15,600 Americans were diagnosed with CLL in 2013. Read More ›

The following sections will assist healthcare professionals and payers by providing appropriate coding and billing information associated with the treatment of melanoma. The following sections include:
  • Associated ICD-9-CM codes used for the classification of melanoma
  • Drugs that have been FDA approved in the treatment of melanoma
  • Drugs that are Compendia-listed for off-label use for melanoma based on clinical studies that suggest beneficial use in some cases. Please note: If a check mark appears in the FDA column, it will NOT appear in the Compendia off-label use column
  • Corresponding HCPCS/CPT® codes and code descriptions
  • Drugs listed in the Compendia section have no FDA-approved uses for melanoma. However, drugs in the FDA-approved section are FDA approved for at least 1 of the melanoma ICD-9-CM codes but may also have Compendia-listed uses as well.
Read More ›

  • Safety Study of SGN-CD33A
  • Decitabine, Cytarabine, and Daunorubicin Hydrochloride
  • Phase 1 Study of IGN523
  • Oral Sapacitabine in Elderly Patients
  • S0919 Idarubicin, Cytarabine, and Pravastatin
  • Oral Azacitidine Plus Best Supportive Care
  • Phase 1b Study of AMG 232 ± Trametinib
  • Clofarabine with Cytarabine Versus Conventional Induction Therapy and NK Cell Transplantation
  • Selinexor in Older Patients
  • Quizartinib Monotherapy Versus Salvage Chemotherapy
Read More ›

Most people are familiar with the old adage about life’s 2 certainties: taxes, like death, are inevitable. But why pay more in taxes than you have to? This article provides 10 potential tax-saving opportunities for 2014. The key is to take the time to evaluate which of these concepts, if any, may work in your situation. There is still time to take advantage of these 10 tax-saving opportunities before December 31, 2014. Read More ›

Many experienced oncology nurses who are retiring or approaching retirement possess knowledge about oncology patient care that comes from years of experience. They have seen a transition from general oncology to specialties in bone marrow transplant, genetics, hematology, medical oncology, palliative care and hospice, radiation oncology, as well as site-specific and surgical oncology. What used to be a limited number of treatment resources has exploded to multiple new methodologies, many of which are based on specific tumor markers. How does a practice ensure that the knowledge, skills, and abilities of its senior nursing staff are transferred to newer nurses joining the practice? Read More ›

Subscribe to
Rheumatology Practice Management

Stay up to date with rheumatology news & updates by subscribing to receive the free RPM print publications or weekly e‑Newsletter.

I'd like to receive: